Cardiff University | Prifysgol Caerdydd ORCA
Online Research @ Cardiff 
WelshClear Cookie - decide language by browser settings

The evaluation of durative transfusion of Endostar combined with chemotherapy in patients with advanced non-small cell lung cancer

Li, Xiaoqin, Gu, Guomin, Soliman, Faris, Sanders, Andrew J., Wang, Xiuli and Liu, Chunling 2018. The evaluation of durative transfusion of Endostar combined with chemotherapy in patients with advanced non-small cell lung cancer. Chemotherapy 63 (4) , p. 214. 10.1159/000493098

[img]
Preview
PDF - Accepted Post-Print Version
Download (550kB) | Preview

Abstract

Background: The overall survival (OS) in non-small cell lung cancer (NSCLC) is poor, with median OS of advanced NSCLC with standard systemic chemotherapy being reported at 13.6 months and the 5-year survival rate at less than 15%. Therefore, the aim of this study was to evaluate Endostar combined with chemotherapy in patients with advanced NSCLC. Methods: Data on 116 cases of pathologically confirmed stage IIIB-IV NSCLC were retrospectively collected. The control group was treated with chemotherapy combined with intravenous infusion of Endostar while the test group received durative transfusion of Endostar. The short-term therapeutic effects including overall response rate (ORR), disease control rate (DCR), and safety were evaluated in both groups. In the follow-up, progression-free survival (PFS) and OS were also analysed. Results: In the test group, the ORR was 53.4%, which was similar to that in the control group (44.8%) (p > 0.05). However, the DCR in the test group (86.2%) was significantly higher than that in the control group (70.7%) (p < 0.01). The median time to progression in the test group (6 months) was also significantly longer than that in the control group (4 months). Importantly, the median OS in the test group (17.5 months) was improved compared to the control group (13.5 months). The 1-year survival rate in the test and control groups was 9.7 and 15.8%, respectively. There was no significant difference in side effects (including thrombocytopenia, leucopenia, nausea, and vomiting) between the two groups. Conclusions: Endostar durative transfusion combined with chemotherapy showed a higher DCR, longer PFS and OS time, and was well tolerated in patients with advanced NSCLC.

Item Type: Article
Date Type: Published Online
Status: Published
Schools: Medicine
Publisher: Karger Publishers
ISSN: 0009-3157
Date of First Compliant Deposit: 29 November 2018
Date of Acceptance: 22 October 2018
Last Modified: 22 Oct 2019 02:18
URI: http://orca.cf.ac.uk/id/eprint/117212

Citation Data

Cited 1 time in Scopus. View in Scopus. Powered By Scopus® Data

Actions (repository staff only)

Edit Item Edit Item

Downloads

Downloads per month over past year

View more statistics